Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 11 Steady uptake of TresibaⓇ in the USA Weekly US NBRx volume market shares Basal NBRX MS 50% 40% 30% 20% 10% 0% Jan 2016 TresibaⓇ Levemir® glargine U100 Note: The graph does not show NPH, which accounts for the residual market share Source: IMS weekly data, 7 October 2016, excludes Medicaid NBRX: New-to-brand prescriptions; MS: Market share changing diabetes TresibaⓇ launched in the USA Full commercial launch in January 2016 following specialist engagement in Q4 2015 • TresibaⓇ volume market share has reached 4.0% NN Total Basal glargine U300 • 46% 31% • TresibaⓇ U200 accounts for nearly 80% of total TresibaⓇ volume 19% 14% 12% Sep 2016 Wide formulary access has been obtained with around 75% access for patients in commercial channels and Medicare part D combined Source: IMS weekly data, 7 October 2016, excludes Medicaid novo nordisk

View entire presentation